Biomarker Testing: Cost and Coverage

Part of the BiomarkerLIVE101 webinar series, Biomarker Testing: Cost and Coverage reviews the current policies and regulations that drive costs related to biomarker testing.

Speakers:

Gabriel Bien-Willner, MD, PhD, Medical Director, MolDX; Chief Medical Officer, Palmetto GBA, Spring, TX 

Hossein Borghaei, DO, MS, Professor and Chief, Thoracic Oncology, The Gloria and Edmund M. Dunn Chair in Thoracic Oncology, Department of Hematology and Oncology, Fox Chase Cancer Center, Philadelphia, PA

This webinar is part of the “BiomarkerLIVE" education program and is supported by AbbVie, AstraZeneca, Lilly Oncology, and Merck & Co., Inc.

You must have an ACCC or state society account to register for this webinar. 

 If You DO NOT Have an Account: 

  • To start, click the green “Register” button in the upper right corner of this page. You will be directed to “Your Cart.” Click the green “Log In” button near the top of the page. 
  • ACCC and State Society Members: Click “Reset Password” to update your login information. When your password is updated, you will be redirected to the “My Profile” page.  
  • Non-members: Click “Create Account.” Once your password is created, you will be redirected to the "My Profile" page.  
  • Click “eLearning” at the top of your profile page to go back to the ACCC eLearning portal. In the box on the left side of the screen, click on the “Cart” link. 
  • The green box in the upper right corner of this page will indicate “You are registered!” for this course! 

If You Have an Account: 

  • Please click the orange “Log In” button on the left side of this screen. You will be taken to the main login page that displays your email and password. Click the “Log in” button. 
  • You will be automatically redirected back to webinar page, and the green box in the upper right corner will say that “You are registered!” for this course! 

PRO TIP: If you save your ACCC password to your computer and remain logged in, you can register for additional webinars and courses in a matter of seconds—with just one click!  

For the best registration and viewing experience, please use Chrome, Edge, or Safari web browsers. Internet Explorer Users may experience difficulties accessing the webinar. 

Once you complete your registration, you will receive an email from ACCC eLearning, which contains information on how to access this webinar. For assistance with registration or if you do not receive an email, please contact registration@accc-cancer.org

Gabriel Bien-Willner, M.D., PhD.

Medical Director, MolDX; Chief Medical Officer, Palmetto GBA

My goal is to fully integrate Genetics and Genomics into the clinical space- to change our approach to cancer care by targeting cancer disease mechanisms to improve patient outcomes. Clinical genomics, through the use of new "Next-Generation" sequencing technologies (NGS) is making this a reality.

Our current focus is on bringing expert clinical interpretation to complex genomics data as a professional service. Current clinical laboratory Next-Gen sequencing test results are simply too complex for most oncologists to fully comprehend. We seek to bridge this gap and provide them with a thorough explanation of the biology of their patient's tumor, as well as relevant targeted treatment options and clinical trials.

I have expertise in NGS clinical and research pipleline development, as well as working with informatics teams to build clinically-relevant systems for complex data annotation and interpretation. I am board certified in Anatomic Pathology and Molecular Genetic Pathology, and have a Ph.D. in Human Molecular Genetics. 

Hossein Borghaei, DO, MS

Professor and Chief, Thoracic Oncology, The Gloria and Edmund M. Dunn Chair in Thoracic Oncology, Deprtment of Hematology and Oncology, Fox Chase Cancer Center

Dr. Hossein Borghaei is chief of thoracic medical oncology and director of the Fox Chase Lung Cancer Center in Philadelphia. As a medical oncologist, he uses anti-cancer drugs to treat lung cancer, mesothelioma, lymphoma and other cancers of the chest. In addition, Borghaei is an active researcher with a special interest in developing new cancer therapies, including immunotherapies that fight cancer by targeting unique proteins and genetic pathways in tumors.

Dr. Borghaei completed his medical training at the Philadelphia College of Osteopathic Medicine, graduating in 1996 with a Master of Science degree in microbiology and immunology. He served his residency at Graduate Hospital in Philadelphia and completed a fellowship in hematology-oncology at the Fox Chase Cancer Center before joining its staff full time in 2004.

Dr. Borghaei has served the role of principal and supporting investigator in numerous clinical trials, which are medical studies that aim to evaluate the safety and effectiveness of new drugs and approaches to treatment. He is currently involved in an active phase II trial that evaluates how pleural mesothelioma patients without progressive disease after first-line chemotherapy benefit from maintenance therapy with Alimta.

His research team is also developing naptumomab estafenatox, a monoclonal antibody for lung and other cancers that activates the body’s immune cells to fight the cancer. In addition, Borghaei conducts clinical trials to improve patients’ immune response to cetuximab and other monoclonal antibodies, which increases their effectiveness.

Dr. Borghaei has authored and coauthored numerous scientific journal articles in his career, most focusing on the topic of immunotherapy for lung cancer and lymphoma. He also served as contributing author and panel member for Malignant Pleural Mesothelioma, a 2012 mesothelioma treatment guide published in the Journal of the National Comprehensive Cancer Network (NCCN).

Dr. Borghaei is a member of several professional medical organizations, including the American Society of Hematology, the American Society of Clinical Oncology and the American Association for Cancer Research.

Additional ACCC Resources to Supplement Your Learning

  • ACCC members can connect in real-time through members-only virtual discussion forum on ACCCeXchange. Within this forum, ACCC members from every profession involved in cancer care delivery ask and answer questions, discuss common challenges, and share knowledge and experience. Join the discussion and connect with your peers.
  • Looking to become a member of the Association of Community Cancer Centers? Visit our membership page for more information on the types of membership we offer and how you can become involved. If you’re unsure whether or not you’re already a member, please contact our membership department today.
  • The ACCCeLearning portal makes it easy to find education relevant to your needs and interests. Accessible on any device and at any time, courses are available in a variety of formats, so you can listen, watch, read or interact in ways that best suit your needs. Health professionals can claim CME/CPE/CNE credit for all applicable activities. Since you’re already logged in, take a look around today!

Key:

Complete
Failed
Available
Locked
On-Demand: Biomarker Testing: Cost and Coverage
Pre-Assessment Survey
1 Question
Biomarker Testing: Cost and Coverage
Open to view video.
Open to view video. We review current policies and regulations that drive costs related to biomarker testing.
Post-Assessment Survey
6 Questions